AIM ImmunoTech (AIM) vs Aprea Therapeutics (APRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AIM ImmunoTech is the larger company by market cap ($7.2 million vs $7.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | APRE |
|---|---|---|
| Share price | $0.1796 | $0.5582 |
| Market cap | $7.17M | $7.03M |
| 1-day change | -1.75% | -7.74% |
| EPS (TTM) | $-2.98 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $1.69 |
| 52-week low | $0.17 | $0.548 |
| Distance from 52-week high | -93.57% | -66.97% |
| Analyst consensus | none | none |
| Avg. price target upside | +2266.37% | +568.22% |
| Average volume | 4.70M | 277.08K |
| Shares outstanding | 39.89M | 12.59M |
| Employees | 19 | 8 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Healthcare · Biotechnology · 19 employees
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Healthcare · Biotechnology · 8 employees
AIM vs APRE FAQ
Which is bigger, AIM ImmunoTech or Aprea Therapeutics?
AIM ImmunoTech (AIM) is larger, with a market capitalization of $7.17M compared with $7.03M for Aprea Therapeutics (APRE).
Are AIM ImmunoTech and Aprea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.